Survodutide Phase 3 Trial Reveals Participant Baselines for Obesity Treatment

Obesity is a global health crisis, significantly increasing the risk of numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. Despite existing treatments, there remains a critical need for highly effective and safe pharmacological interventions to achieve substantial and sustained weight loss. This study addresses the initial characterization of participants in a large-scale Phase 3 clinical trial evaluating Survodutide for obesity.

This paper primarily details the demographic and clinical characteristics of the study population at the start of the trial. The cohort comprised a diverse group of individuals with obesity, with an average age of 49.5 years and a mean baseline body mass index (BMI) of 37.2 kg/m². Approximately 65% of participants were female, and 78% had at least one obesity-related comorbidity, such as hypertension (45%) or dyslipidemia (30%). The study confirmed a well-balanced distribution of these baseline characteristics across the treatment and placebo arms, which is crucial for the integrity of a randomized controlled trial. The robust and diverse baseline characteristics of the SYNCHRONIZE™-1 cohort underscore the trial's potential to provide generalizable and clinically meaningful data on Survodutide's efficacy and safety for a broad population living with obesity. No efficacy or safety outcomes were reported in this specific publication, as its focus was solely on the initial participant profiles.